 |
|
|
| Home -> Products & Services -> Kinase Expression Plasmid Vectors -> KIF5B-RET Fusion Expression Plasmid Vectors | ||
| Quick Inquiry |
KIF5B-RET Fusion Expression Plasmid Vectors The KIF5B-RET fusion gene is formed by a chromosomal translocation between the kinesin family member KIF5B and the RET proto-oncogene. It is commonly found in non-small cell lung cancer (NSCLC) and papillary thyroid carcinoma (PTC). This fusion leads to constitutive activation of the RET kinase domain, promoting tumor proliferation and metastasis through signaling pathways such as RAS/MAPK and PI3K/AKT. In NSCLC, RET fusions are detected in 1%-2% of patients, but the prevalence can reach 7%-17% in young, non-smoking lung adenocarcinoma patients. RGBiotech offers KIF5B-RET expression plasmid vector products and construction services. For KIF5B-RET fusion expression plasmid vector products or custom construction services, please consult our technical team at admin@rgbiotech.com for detailed information. Product List for KIF5B-RET Fusion Expression Plasmid Vectors
Applications 1) Basic Research: Provide KIF5B-RET expression vectors for researchers to study basic scientific issues such as the functions of the KIF5B-RET fusion gene, the signaling mechanism, and its role in tumor occurrence and development, helping to gain an in-depth understanding of the pathogenesis of related cancers.2) Drug Development: The constructed KIF5B-RET expression vectors can be used to establish cell models and animal models for screening and evaluating targeted drugs against the KIF5B-RET fusion protein, as well as studying the mechanism of action, efficacy, and safety of drugs, providing powerful tools for anti-cancer drug development. 3) Diagnostic Technology Development: Based on the KIF5B-RET expression vectors, diagnostic reagents and methods for detecting the KIF5B-RET fusion gene, such as fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR), are developed, which is helpful for the early diagnosis and precise typing of cancers. Why Choose RGBiotech? 1. Professional Technical Team: Our professional technical team has rich experience and professional knowledge in gene vector construction, cell culture, and molecular detection, and can provide customers with high-quality KIF5B-RET expression vector products and construction services.2. Gene Sequencing Verification: Full gene sequencing is carried out on the constructed KIF5B-RET expression vectors to ensure that the inserted gene sequences are accurate and consistent with the target sequences provided by customers, avoiding gene mutations and incorrect cloning. 3. Multiple Vector Options: A variety of types of expression vectors are provided for customers to choose from, such as plasmid vectors and viral vectors (lentiviral vectors, adenoviral vectors, etc.), which can be reasonably matched according to customers' experimental needs and application scenarios. 4. Customized Construction: According to the specific needs of customers, personalized KIF5B-RET expression vector construction solutions are provided, including vector type selection, gene sequence optimization, tag addition, etc., to meet the needs of different customers in basic research and drug development. Read More KIF5B (Kinesin Family Member 5B) and RET (Rearranged during Transfection) are originally two important genes within cells. Under certain circumstances, the KIF5B gene and the RET gene will fuse to form the KIF5B-RET fusion gene, which in turn expresses the KIF5B-RET fusion protein. This fusion alters the normal functions of the original genes, causing abnormal activation of the intracellular signaling pathways. KIF5B-RET fusion is mainly found in patients with lung adenocarcinoma. Among all patients with non-small cell lung cancer (NSCLC), KIF5B-RET fusion accounts for approximately 2%. It mostly occurs in non-smoking patients, and the tumors of these patients rarely have other genetic alterations among the known cancer driver genes. Non-small cell lung cancer (NSCLC) is the disease most closely related to KIF5B-RET fusion. KIF5B-RET fusion promotes the malignant biological behaviors of lung adenocarcinoma cells, leading to tumor occurrence and development, by activating a series of signaling pathways related to cell proliferation, survival, migration, and invasion, such as the RAS/MAPK and PI3K/AKT pathways. Although KIF5B-RET fusion has been most studied in NSCLC, it has also been rarely reported in some other cancer types, such as thyroid cancer. However, the specific mechanisms of occurrence and its role in these cancers still require further in-depth research. Inhibitors Related to KIF5B-RET 1) Pralsetinib: It is a highly selective RET inhibitor that can specifically inhibit the activity of the RET kinase, thereby blocking the abnormal signaling mediated by the KIF5B-RET fusion protein and effectively inhibiting the proliferation of cells expressing RET gene variants. It has been approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with RET gene fusion.2) Selpercatinib: It is also a highly selective RET inhibitor and has shown good efficacy in the treatment of cancers related to RET gene fusion. As a single agent, it can achieve a certain objective response rate in previously treated NSCLC patients as well as treatment-naive patients. In the thyroid cancer cohort, whether in patients who have failed multiple lines of treatment or treatment-naive patients, it also has a high response rate. In the cohort of rare tumors other than lung cancer and thyroid cancer, it can also benefit some patients. However, studies have found that the use of RET inhibitors alone sometimes does not achieve ideal results in tumor cells positive for KIF5B-RET fusion. The KIF5B-RET fusion protein, through its N-terminal KIF5B domain and C-terminal RET kinase domain, establishes a RET-SRC-EGFR-FGFR "signaling hub" that depends on microtubules and Rab vesicles. Therefore, the combined use of drugs targeting multiple targets, such as combining the RET inhibitor sorafenib with drugs targeting EGFR, microtubules, or FGFR, has shown stronger efficacy in Drosophila and human cell line KIF5B-RET models. Research Hotspots 1) Exploration of Combination Therapy Regimens: Given the limitations of single RET inhibitors, studying how to combine RET inhibitors with other targeted drugs, chemotherapy drugs, or immunotherapy drugs to improve treatment effects and overcome drug resistance is one of the current hotspots. For example, studying the efficacy and safety of combining RET inhibitors with EGFR inhibitors, anti-angiogenic drugs, etc. in NSCLC patients positive for KIF5B-RET fusion.2) Research on Drug Resistance Mechanisms: With the application of targeted therapies, the problem of drug resistance has gradually become prominent. In-depth research on the molecular mechanisms by which KIF5B-RET fusion-positive tumors develop resistance to RET inhibitors is helpful for the development of new treatment strategies to overcome drug resistance, such as finding new drug resistance-related targets and exploring combination treatment regimens to overcome drug resistance. 3) Detection of KIF5B-RET Fusion by Liquid Biopsy: Compared with tissue biopsy, liquid biopsy has the advantages of being minimally invasive and repeatable. Studying how to accurately detect KIF5B-RET fusion by detecting cell-free DNA (cfDNA) or circulating tumor cells (CTCs) in body fluids such as blood and pleural effusion is used for early cancer diagnosis, treatment effect monitoring, and recurrence prediction. Research Challenges 1) Complex Signaling Pathways: The signaling pathway network activated by the KIF5B-RET fusion protein is very complex, involving multiple upstream and downstream molecules and interactions. It is difficult to comprehensively and deeply understand the regulatory mechanisms of these signaling pathways and the cross-talk between them, which also poses a challenge to the development of precise and effective treatment strategies.2) Patient Heterogeneity: There is great heterogeneity in the molecular characteristics, clinicopathological features, and responses to treatment among KIF5B-RET fusion-positive tumors in different patients. How to develop personalized treatment plans according to the individual differences of patients is one of the difficulties. 3) Limitations of Animal Models: Although the animal models currently used to study KIF5B-RET-related cancers can simulate human diseases to a certain extent, there are still differences from the real clinical situation, which may affect the translation of research results into clinical applications. |
|
|
Products & Services Resources | ||
|
Home Products & Services Support About Us Contact Us |
Promotions Flyers Brochures Publications News & Events |
Terms & Conditions Privacy Disclaimers |
Contact Us EMAIL: admin@rgbiotech.com |
||
| © RGBiotech All Rights Reserved. | |||||